While SF3B1, a splicing factor frequently mutated in cancers [88,89,90,91,92,93,94,95,96,97], is often targeted in therapies, these neoepitopes were present regardless of SF3B1 mutation status, suggesting an SF3B1-independent mechanism of action. This evidence concerns the gene SF3B1 and cancer.